Canagliflozin is Most Responsible for the Acid-Base Disorder
Canagliflozin (the SGLT2 inhibitor) is the most likely culprit for this patient's ketoacidosis, presenting as euglycemic diabetic ketoacidosis (euDKA). The clinical presentation—nausea, vomiting, abdominal pain, positive urine ketones, low bicarbonate, and a glucose of only 155 mg/dL—is pathognomonic for SGLT2 inhibitor-associated euDKA 1.
Why Canagliflozin is the Primary Culprit
The FDA label explicitly warns that SGLT2 inhibitors like canagliflozin cause ketoacidosis even with blood glucose levels below those typically expected for DKA (e.g., less than 250 mg/dL) 1. This patient's glucose of 155 mg/dL fits this pattern perfectly. Key precipitating factors present in this case include:
- Under-insulinization: She discontinued insulin one week ago 1
- Reduced caloric intake: Implied by nausea and vomiting 1
- Classic symptoms: Nausea, vomiting, abdominal pain, and generalized malaise are the hallmark presentation 1, 2
Recent guidelines emphasize that SGLT2 inhibitors carry specific risk for euglycemic DKA, particularly in hospitalized patients with poor oral intake 3. The Canadian cardiovascular guidelines note that nonspecific symptoms of DKA include nausea, vomiting, and abdominal pain—exactly what this patient exhibits 4.
Why Not the Other Medications
Metformin
While metformin can cause lactic acidosis, this occurs primarily in patients with:
- Significant renal impairment (eGFR <30 mL/min/1.73 m²) 3
- Sepsis, hypoxia, or shock 3
- Severe hepatic dysfunction 3
This patient's creatinine of 1.3 suggests only mild renal impairment, and there's no mention of sepsis or hypoxia. Most importantly, metformin causes lactic acidosis, not ketoacidosis—and this patient has positive urine ketones 3, 5.
Rosuvastatin
Statins do not cause metabolic acidosis or ketoacidosis. This medication is irrelevant to the acid-base disorder.
Sitagliptin (DPP-4 inhibitor, likely what "semi glue tide" refers to)
DPP-4 inhibitors do not cause ketoacidosis or metabolic acidosis. They have a neutral effect on acid-base balance.
Critical Clinical Pearls
The most dangerous pitfall is missing euDKA because the glucose isn't dramatically elevated. Multiple case reports demonstrate that nearly half of SGLT2 inhibitor-associated DKA cases present with glucose <250 mg/dL 2. Emergency physicians and hospitalists must check ketones in any SGLT2 inhibitor-treated patient presenting with nausea, vomiting, and abdominal pain, regardless of glucose level 1, 6.
The FDA label specifically states to "assess for ketoacidosis regardless of presenting blood glucose levels in patients who present with signs and symptoms consistent with severe metabolic acidosis" 1. This patient meets all criteria.
Additional Considerations
The elevated potassium (6.0) and elevated creatinine (1.3) likely reflect:
- Volume depletion from vomiting and SGLT2 inhibitor-induced osmotic diuresis
- Acute kidney injury from hypovolemia
- Acidosis-induced potassium shift from intracellular to extracellular space
The combination of canagliflozin and metformin theoretically increases metabolic acidosis risk through dual mechanisms 7, but the ketoacidosis with positive urine ketones definitively points to the SGLT2 inhibitor as the primary driver.
Immediate Management
- Discontinue canagliflozin immediately 1
- Confirm DKA with beta-hydroxybutyrate level
- Initiate IV insulin infusion with dextrose-containing fluids (since glucose is not severely elevated)
- Aggressive volume resuscitation
- Monitor for resolution of ketoacidosis before considering restarting any SGLT2 inhibitor 1
Note that urinary glucose excretion can persist for 3+ days after discontinuing canagliflozin, with some cases lasting up to 2 weeks 1, 8. Continue monitoring and maintain adequate hydration during this period.